Senesce to Survive: YAP-Mediated Dormancy Escapes EGFR/MEK Inhibition.
暂无分享，去创建一个
[1] Henry W. Long,et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. , 2020, Cancer cell.
[2] H. Shan,et al. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD , 2018, Cell Death & Disease.
[3] N. Sharpless,et al. Forging a signature of in vivo senescence , 2015, Nature Reviews Cancer.
[4] P. Jänne,et al. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. , 2015, Cancer discovery.
[5] Antonio Marchetti,et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies , 2015, Nature Genetics.
[6] David M. Thomas,et al. The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.
[7] Yosef Yarden,et al. Feedback regulation of EGFR signalling: decision making by early and delayed loops , 2011, Nature Reviews Molecular Cell Biology.
[8] D. Peeper,et al. The essence of senescence. , 2010, Genes & development.
[9] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[10] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.